Secalonic acid D induces cell apoptosis in both sensitive and ABCG2-overexpressing multidrug resistant cancer cells...

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Secalonic acid D (SAD) demonstrates anti-proliferative effects on various cancer cells.
• The precise molecular mechanisms underlying SAD's action, particularly in multidrug-resistant (MDR) cells, require further investigation.

Purpose of the Study:

• To elucidate the molecular mechanisms by which SAD induces cancer cell death.
• To investigate SAD's efficacy against both sensitive and MDR cancer cell lines.
• To identify the specific signaling pathways involved in SAD-induced apoptosis.

Main Methods:

• Cytotoxicity assays were performed on sensitive and MDR cell lines (S1-MI-80/S1, H460/MX20/H460, MCF-7/ADR/MCF-7).
• Cell cycle analysis was conducted to assess the effect of SAD on cell cycle progression.
• Western blotting and kinase assays were used to analyze protein expression and phosphorylation levels of key signaling molecules (e.g., cyclin B1, CDC2, c-Jun, JNK, Src, STAT3).
• Proteasome-dependent degradation assays were performed to determine the effect of SAD on c-Jun protein stability.

Main Results:

• SAD exhibited potent cytotoxicity against sensitive and MDR cancer cells.
• SAD induced G2/M phase arrest by downregulating cyclin B1 and increasing CDC2 phosphorylation.
• SAD activated the JNK pathway, leading to increased c-Jun protein expression and phosphorylation.
• SAD inhibited the proteasome-dependent degradation of c-Jun, stabilizing the protein.
• The c-Jun/Src/STAT3 signaling axis was identified as crucial for SAD-induced apoptosis.

Conclusions:

• SAD induces cancer cell death through the c-Jun/Src/STAT3 signaling pathway.
• Inhibition of c-Jun proteasome-dependent degradation is a key mechanism for SAD-induced apoptosis.
• SAD shows promise as a therapeutic agent against both sensitive and ABCG2-mediated MDR cancers.